A heart medicine has repeatedly appeared in sports doping cases

A heart medicine has repeatedly appeared in sports doping cases
Image: Intellect (generated)

In short: Trimetazidine was developed to ease chest pain caused by poor blood flow to the heart. It works by shifting heart cells toward burning glucose rather than fatty acids, which uses less oxygen. That same metabolic effect led sports authorities to add it to their banned list in 2014, and several athletes have since tested positive.

Trimetazidine is used for long-term treatment of angina pectoris, the chest pain that occurs when the heart receives too little blood. Laboratoires Servier in France developed and first marketed it, and it is regarded as an early drug of its kind that protects heart cells under stress. It belongs to the class of fatty acid oxidation inhibitors. Instead of widening blood vessels, it changes how heart cells produce their energy. The mechanism is specific. Cells normally make ATP, their main energy currency, by burning both fatty acids and glucose. When oxygen is limited, fatty acid burning becomes inefficient. Trimetazidine blocks a mitochondrial enzyme involved in fatty acid breakdown, so cells lean on glucose, which yields more ATP per unit of oxygen. Preserving ATP helps energy-dependent processes, such as ion pumps, keep working during ischaemic stress. Controlled studies in angina patients reported increased coronary flow reserve, later onset of exercise-induced ischaemia and fewer angina attacks. The evidence has limits.

Information about its effect on death rates, heart events or overall wellbeing is scarce, so the authors argue that long-term randomised trials against standard drugs would be justified. A 2013 retrospective cohort study suggested benefit in heart failure patients, but that is observational evidence. In 2012 the European Medicines Agency restricted its use to add-on therapy when first-line drugs are insufficient or not tolerated. It also reported rare Parkinson-like movement disorders, so doctors are advised against prescribing it to certain patients. Its sporting history is contested. Added to the World Anti-Doping Agency's prohibited list in 2014, it has been linked to several cases, including swimmer Sun Yang and figure skater Kamila Valieva. Doping expert Klaas Faber criticised inconsistent rules and called for thresholds to avoid inadvertent positives. Heart specialists Benjamin Levine and Aaron Baggish doubted it would help a figure skater, though Baggish noted it might theoretically aid endurance athletes.

The story shows how a medicine can be useful and still contested.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/health-trimetazidine.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…